Central Pattana's (BKK:CPN) attributable profit rose 10% to 4.75 billion baht in the second quarter of 2026, from 4.30 billion baht a year ago, according to a Monday filing to the Thai stock exchange.
Earnings per share in Q2 climbed to 1.06 baht from 0.96 baht a year earlier, the real estate developer said.
Total revenue in the three months ended June 30 also increased 8% year-on-year to 12.1 billion baht from 13.1 billion baht a year ago.
Aspial Lifestyle's (SGX:5UF) recorded an 88% rise in attributable profit in the first half of 2026 to SG$52.4 million from SG$27.9 million a year prior.Earnings per share stood at SG$0.0277, up from SG$0.015 previously, according to a Friday filing with the Singapore bourse.Revenue jumped 26% to SG$464.2 million from SG$367.2 million in the year-ago period.
Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's Benmelstobart Injection obtained marketing approval from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approval is for use of the drug in combination with chemotherapy and sequentially followed by Anlotinib Hydrochloride Capsules for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.
Lygend Resources & Technology (HKG:2245) obtained approval for its registration application related to its China listed-share initial public offering from the China Securities Regulatory Commission (CSRC).The share offering is subject to various conditions, including certain final regulatory approvals, according to a Friday Hong Kong bourse filing.